|
MechanismGnRHR antagonists |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with S&K Holdings, Inc.
0 Patents (Medical) associated with S&K Holdings, Inc.
100 Deals associated with S&K Holdings, Inc.
100 Translational Medicine associated with S&K Holdings, Inc.